Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

<p class="Briefs-First"> Most patients receive antiplatelet treatment after an acute coronary syndrome. Combinations of antiplatelet agents reduce risk of recurrent MI &mdash; particularly stent thrombosis &mdash; but do have a modest increase in bleeding risk. Well, what about our post-MI patients who are taking appropriately prescribed antiplatelet agents who also require treatment with NSAIDs for disorders like osteoarthritis, migraine, etc? How does such multidrug co-administration affect risks?</p>

Consequences of NSAID Use in Patients Receiving Post-MI Antithrombotic Prophylaxis